Table 1.
Indication and major endocrinopathies of immune checkpoint inhibitors (ICIs).
| Target | Drug | Indication | Major Endocrinopathies |
|---|---|---|---|
| Anti CTLA-4 antibody | Ipilimumab | Malignant melanoma | Hypopituitarism |
| Renal cell cancer | |||
| Anti-PD-1 antibody | Nivolumab | Malignant melanoma | Hypothyroidism Hyperthyroidism |
| Non-small cell lung cancer | |||
| Renal cell cancer | |||
| Hodgkin lymphoma | |||
| Head and neck cancer | |||
| Gastric cancer | |||
| Malignant mesothelioma | |||
| Colorectal cancer with high-frequency microsatellite instability (MSI-High) | |||
| Esophageal cancer | |||
| Pembrolizumab | Non-small cell lung cancer | Hypothyroidism Hyperthyroidism |
|
| Hodgkin lymphoma | |||
| Urothelial cancer | |||
| Solid cancers with high-frequency microsatellite instability (MSI-High) | |||
| Renal cell cancer | |||
| Head and neck cancer | |||
| Anti PD-L1 antibody | Atezolizumab | Non-small cell lung cancer | Hypothyroidism |
| Small cell lung cancer | |||
| Breast cancer | |||
| Durvalumab | Non-small cell lung cancer | Hypothyroidism | |
| Hyperthyroidism | |||
| Avelumab | Merkel cell carcinoma renal cell cancer | Hypothyroidism |
PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T-lymphocyte antigen-4.